The US Food and Drug Administration (FDA) has granted fast track designation to Rznomics' RZ-001 for the treatment of ...
US FDA grants fast track designation to Rznomics’ gene therapy-based cancer drug candidate, RZ-001: Seongnam, South Korea Wednesday, February 19, 2025, 16:00 Hrs [IST] Rznomics, ...
Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC ...
The US Food and Drug Administration (FDA) has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC), a form of liver cancer. This is the second ...
Anticancer drug utilizing Trans-splicing Ribozyme technology Second Fast Track Designation following brain cancer approval SEONGNAM, South Korea, Feb. 18, 2025 /PRNewswire/ -- Rznomics announced ...